Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R.sup.2 is alkyl having from 1 to 3 carbon atoms; R.sup.3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 ...

An improved method for the treatment of central nervous system disorders comprises treating patients with an enteric fluoxetine formulation.

The invention provides a method of detecting, analyzing sleep disorders. The method includes the step of monitoring sound produced by a sleeping subject through a sensor proximate the sleeping subject and continuously recording the monitored sound. The method further includes identifying snoring within the recorded sound and analyzing the identified snoring to localize upper airway structural sources of snoring.

Novel piperidyl-indoles of the formula ##STR1## wherein X is selected from the group consisting of fluorine, chlorine and bromine when Y and Z are hydrogen or together form a double bond and X is selected from the group consisting of hydrogen and alkoxy of 1 to 3 carbon atoms when Y and Z form a double bond and their non-toxic, pharmaceutically acceptable acid addition salts having antidepressant, antiemetic and antiparkinsonian activity and their preparations and novel intermediates therefore.

The invention relates to the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.

A method for treating skin disorders in warm-blooded animals, said method comprising administering to said warm-blooded animals an effective amount of an appropriately substituted benzimidazole or benzotriazole which suppresses the metabolism of retinoids. Compositions comprising said compounds and an effective amount of a retinoid.

The use of a compound of formula I ##STR1## wherein R is a hydrogen atom or a group selected from C.sub.1-6 alkyl (optionally substituted by C.sub.3-7 cycloalkyl), C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, C.sub.3-7 cycloalkyl, aralkyl (in which the alkyl moiety contains 1-5 carbon atoms) and --CHO; R.sup.1 and R.sup.2, which may be the same or different, represent a hydrogen atom, a halogen atom or a group selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxyl, cyano, nitro and --NR.sup.3 R.sup....

A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders as disclosed. The method includes administering to a patient a composition comprising an effective haemostatic amount of factor VIIa, and is particularly effective in treating patients suffering from thrombocytopenia and von Willebrand's disease, as well as other platelet disorders. A compositio...

A method of resisting neurological damage caused by overstimulation of the NMDA receptor of nerve cells by glutamate includes exposing the NMDA receptors to an oxidizing agent to thereby diminish overall activity of the receptors following activation by glutamate. The oxidizing agent preferably is a material selected from the group consisting of pyrroloquinoline quinone and topa hydantoin.

Methods are described for characterizing platelet aggregation defects. The defects are characterized as activation, ligand binding, or post-occupancy defects. In one embodiment of the invention a Cam variant of Glanzmann's thrombasthenia is characterized as having a ligand binding defect. In another embodiment, a patient with myelofibrosis is identified as having an activation defect. Rapid analysis are afforded using fluorescence-activated flow cytometry. Also, diagnostic kits are described whi...